Connective tissue disease-associated interstitial lung disease: from pathogenesis to

doi:10.11958/20240260

Abstract

Abstract:

Connective tissue diseases (CTD) are a spectrum of heterogeneous diseases with multiple organ involvements. Interstitial lung diseases (ILD) are serious complications of CTD. There is great heterogeneity in pathogenesis, clinical manifestations, and treatment of different CTD-ILD. Previous basic and clinical studies have explored the pathogenesis of CTD-ILD, and the "dual-target" treatment strategy has therefore emerged. The implementation of the "dual-target" treatment strategy helps to control CTD activity and lung inflammation in the early stage, prevent the progression of pulmonary fibrosis, and thus improve patient survival and quality of life.

Key words: connective tissue diseases, lung diseases, interstitial, diagnosis, therapy, pathogenesis

CLC Number:

R593.2

References 47

[1]	MIRA-AVENDANO I, ABRIL A, BURGER C D, et al. Interstitial lung disease and other pulmonary manifestations in connective tissue diseases[J]. Mayo Clin Proc, 2019, 94(2):309-325. doi:10.1016/j.mayocp.2018.09.002.
[2]	MATHAI S C, DANOFF S K. Management of interstitial lung disease associated with connective tissue disease[J]. BMJ, 2016,352:h6819. doi:10.1136/bmj.h6819.
[3]	JOY G M, ARBIV O A, WONG C K, et al. Prevalence,imaging patterns and risk factors of interstitial lung disease in connective tissue disease:a systematic review and meta-analysis[J]. Eur Respir Rev, 2023, 32(167):220210. doi:10.1183/16000617.0210-2022.
[4]	中国医师协会风湿免疫科医师分会风湿病相关肺血管/间质病学组, 国家风湿病数据中心. 2018中国结缔组织病相关间质性肺病诊断和治疗专家共识[J]. 中华内科杂志, 2018, 57(8):558-565.
	Rheumatology Related Pulmonary Vascular/Interstitial Epidemiology Group, Rheumatology and Immunology Division,Chinese Medical Doctor Association,National Rheumatology Data Center. 2018 Chinese expert-based consensus statement regarding the diagnosis and treatment of interstitial lung disease associated with connective tissue diseases[J]. Chin J Intern Med, 2018, 57(8):558-565. doi:10.3760/cma.j.issn.0578-1426.2018.08.005.
[5]	SHAO T, SHI X, YANG S, et al. Interstitial lung disease in connective tissue disease: a common lesion with heterogeneous mechanisms and treatment considerations[J]. Front Immunol, 2021,12:684699. doi:10.3389/fimmu.2021.684699.
[6]	CERRO CHIANG G, PARIMON T. Understanding interstitial lung diseases associated with connective tissue disease(CTD-ILD):genetics,cellular pathophysiology,and biologic drivers[J]. Int J Mol Sci, 2023, 24(3):2405. doi:10.3390/ijms24032405.
[7]	SPAGNOLO P, DISTLER O, RYERSON C J, et al. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)[J]. Ann Rheum Dis, 2021, 80(2):143-150. doi:10.1136/annrheumdis-2020-217230.
[8]	TSENG C C, SUNG Y W, CHEN K Y, et al. The Role of Macrophages in connective tissue disease-associated interstitial lung disease: focusing on molecular mechanisms and potential treatment strategies[J]. Int J Mol Sci, 2023, 24(15):11995. doi:10.3390/ijms241511995.
[9]	WU Y, LI Y, LUO Y, et al. Proteomics: potential techniques for discovering the pathogenesis of connective tissue diseases-interstitial lung disease[J]. Front Immunol, 2023,14:1146904. doi:10.3389/fimmu.2023.1146904.
[10]	SCHER J U, JOSHUA V, ARTACHO A, et al. The lung microbiota in early rheumatoid arthritis and autoimmunity[J]. Microbiome, 2016, 4(1):60. doi:10.1186/s40168-016-0206-x.
[11]	ANDRÉASSON K, LEE S M, LAGISHETTY V, et al. Disease features and gastrointestinal microbial composition in patients with systemic sclerosis from two independent cohorts[J]. ACR Open Rheumatol, 2022, 4(5):417-425. doi:10.1002/acr2.11387.
[12]	VERES-SZÉKELY A, SZÁSZ C, PAP D, et al. Zonulin as a potential therapeutic target in microbiota-gut-brain axis disorders: encouraging results and emerging questions[J]. Int J Mol Sci, 2023, 24(8):7548. doi:10.3390/ijms24087548.
[13]	DRAKOPANAGIOTAKIS F, STAVROPOULOU E, TSIGALOU C, et al. The role of the microbiome in connective-tissue-associated interstitial lung disease and pulmonary vasculitis[J]. Biomedicines, 2022, 10(12):3195. doi:10.3390/biomedicines10123195.
[14]	JEON H, NAM B D, YOON C H, et al. Radiologic approach and progressive exploration of connective tissue disease-related interstitial lung disease: meeting the curiosity of rheumatologists[J]. J Rheum Dis, 2024, 31(1):3-14. doi:10.4078/jrd.2023.0042.
[15]	PUGASHETTI J V, KHANNA D, KAZEROONI E A, et al. Clinically relevant biomarkers in connective tissue disease-associated interstitial lung disease[J]. Immunol Allergy Clin North Am, 2023, 43(2):411-433. doi:10.1016/j.iac.2023.01.012.
[16]	ANTHIMOPOULOS M, CHRISTODOULIDIS S, EBNER L, et al. Lung pattern classification for interstitial lung diseases using a deep convolutional neural network[J]. IEEE Trans Med Imaging, 2016, 35(5):1207-1216. doi:10.1109/TMI.2016.2535865.
[17]	JACOB J, HIRANI N, VAN MOORSEL C, et al. Predicting outcomes in rheumatoid arthritis related interstitial lung disease[J]. Eur Respir J, 2019, 53(1): 1800869. doi:10.1183/13993003.00869-2018.
[18]	WANG Y, GARGANI L, BARSKOVA T, et al. Usefulness of lung ultrasound B-lines in connective tissue disease-associated interstitial lung disease:a literature review[J]. Arthritis Res Ther, 2017, 19(1):206. doi:10.1186/s13075-017-1409-7.
[19]	WANG Y, CHEN S, ZHENG S, et al. The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease:review of the literature,proposal for a preliminary algorithm,and clinical application to cases[J]. Arthritis Res Ther, 2021, 23(1):212. doi:10.1186/s13075-021-02586-9.
[20]	BROENS B, DUITMAN J W, ZWEZERIJNEN G, et al. Novel tracers for molecular imaging of interstitial lung disease:A state of the art review[J]. Autoimmun Rev, 2022, 21(12):103202. doi:10.1016/j.autrev.2022.103202.
[21]	MARIE I, JOSSE S, DECAUX O, et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome[J]. Autoimmun Rev, 2012, 11(10):739-745. doi:10.1016/j.autrev.2012.01.006.
[22]	MIĄDLIKOWSKA E, RZEPKA-WRONA P, MIłKOWSKA-DYMANOWSKA J, et al. Review:serum biomarkers of lung fibrosis in interstitial pneumonia with autoimmune features-what do we already know?[J]. J Clin Med, 2021, 11(1):89. doi:10.3390/jcm11010079.
[23]	TOMASSETTI S, COLBY T V, WELLS A U, et al. Bronchoalveolar lavage and lung biopsy in connective tissue diseases,to do or not to do?[J]. Ther Adv Musculoskelet Dis, 2021,13:1759720X211059605. doi:10.1177/1759720X211059605.
[24]	JAEGER V K, WIRZ E G, ALLANORE Y, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal eustar study[J]. PLoS One, 2016, 11(10):e0163894. doi:10.1371/journal.pone.0163894.
[25]	ZAMORA-LEGOFF J A, KRAUSE M L, CROWSON C S, et al. Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease[J]. Arthritis Rheumatol, 2017, 69(3):542-549. doi:10.1002/art.39971.
[26]	MARIE I, HATRON P Y, DOMINIQUE S, et al. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients[J]. Arthritis Rheum, 2011, 63(11):3439-3447. doi:10.1002/art.30513.
[27]	PARAMBIL J G, MYERS J L, LINDELL R M, et al. Interstitial lung disease in primary Sjögren syndrome[J]. Chest, 2006, 130(5):1489-1495. doi:10.1378/chest.130.5.1489.
[28]	AHMED S, HANDA R. Management of connective tissue disease-related interstitial lung disease[J]. Curr Pulmonol Rep, 2022, 11(3):86-98. doi:10.1007/s13665-022-00290-w.
[29]	WILSON T M, SOLOMON J J, DEMORUELLE M K. Treatment approach to connective tissue disease-associated interstitial lung disease[J]. Curr Opin Pharmacol, 2022,65:102245. doi:10.1016/j.coph.2022.102245.
[30]	American College of Rheumatology Empowering Rheumatology Professionals. 2023 American College of Rheumatology(ACR)guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic disease[EB/OL]. (2023-08-23)[2024-03-06]. https://rheumatology.org/interstitial-lung-disease-guideline#2023-ild-guideline.
[31]	BARNES H, HOLLAND A E, WESTALL G P, et al. Cyclophosphamide for connective tissue disease-associated interstitial lung disease[J]. Cochrane Database Syst Rev, 2018, 1(1):CD010908. doi:10.1002/14651858.CD010908.pub2.
[32]	BARBA T, FORT R, COTTIN V, et al. Treatment of idiopathic inflammatory myositis associated interstitial lung disease:A systematic review and meta-analysis[J]. Autoimmun Rev, 2019, 18(2):113-122. doi:10.1016/j.autrev.2018.07.013.
[33]	MATSON S M, BAQIR M, MOUA T, et al. Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world,multisite study of the impact of immunosuppression on pulmonary function trajectory[J]. Chest, 2023, 163(4):861-869. doi:10.1016/j.chest.2022.11.035.
[34]	MAHER T M, TUDOR V A, SAUNDERS P, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL):a double-blind,double-dummy,randomised,controlled,phase 2b trial[J]. Lancet Respir Med, 2023, 11(1):45-54. doi:10.1016/S2213-2600(22)00359-9.
[35]	ASSASSI S, VOLKMANN E R, ZHENG W J, et al. Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease[J]. Ann Rheum Dis, 2022, 81(6):854-860. doi:10.1136/annrheumdis-2021-221313.
[36]	KARAKONTAKI F V, PANSELINAS E S, POLYCHRONOPOULOS V S, et al. Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status and future development[J]. Autoimmun Rev, 2021, 20(2):102742. doi:10.1016/j.autrev.2020.102742.
[37]	HUAPAYA J A, SILHAN L, PINAL-FERNANDEZ I, et al. Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease[J]. Chest, 2019, 156(5):896-906. doi:10.1016/j.chest.2019.05.023.
[38]	KHANNA D, LIN C, FURST D E, et al. Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: open-label extension of a phase 3 randomized controlled trial[J]. Am J Respir Crit Care Med, 2022, 205(6):674-684. doi:10.1164/rccm.202103-0714OC.
[39]	ROOFEH D, LIN C, GOLDIN J, et al. Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease[J]. Arthritis Rheumatol, 2021, 73(7):1301-1310. doi:10.1002/art.41668.
[40]	VICENTE-RABANEDA E F, ATIENZA-MATEO B, BLANCO R, et al. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis:A systematic literature review[J]. Autoimmun Rev, 2021, 20(6):102830. doi:10.1016/j.autrev.2021.102830.
[41]	BELLAN M, PATRUCCO F, BARONE-ADESI F, et al. Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases:A systematic review[J]. Autoimmun Rev, 2020, 19(2):102453. doi:10.1016/j.autrev.2019.102453.
[42]	KHANNA D, LESCOAT A, ROOFEH D, et al. Systemic sclerosis-associated interstitial lung disease: how to incorporate two food and drug administration-approved therapies in clinical practice[J]. Arthritis Rheumatol, 2022, 74(1):13-27. doi:10.1002/art.41933.
[43]	HIGHLAND K B, DISTLER O, KUWANA M, et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate:a subgroup analysis of the SENSCIS trial[J]. Lancet Respir Med, 2021, 9(1):96-106. doi:10.1016/S2213-2600(20)30330-1.
[44]	SEIBOLD J R, MAHER T M, HIGHLAND K B, et al. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease:data from the SENSCIS trial[J]. Ann Rheum Dis, 2020, 79(11):1478-1484. doi:10.1136/annrheumdis-2020-217331.
[45]	DISTLER O, HIGHLAND K B, GAHLEMANN M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease[J]. N Engl J Med, 2019, 380(26):2518-2528. doi:10.1056/NEJMoa1903076.
[46]	PECHER A C, HENSEN L, KLEIN R, et al. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome[J]. JAMA, 2023, 329(24):2154-2162. doi:10.1001/jama.2023.8753.
[47]	PERELAS A, SILVER R M, ARROSSI A V, et al. Systemic sclerosis-associated interstitial lung disease[J]. Lancet Respir Med, 2020, 8(3):304-320. doi:10.1016/S2213-2600(19)30480-1.

Connective tissue disease-associated interstitial lung disease: from pathogenesis to "dual-target" treatment strategies

Cite this article

RichHTML

PDF (PC)

Knowledge

Abstract

share this article

References 47

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	JIN Fang, FENG Jing. The rapid pathological diagnostic value of cytological smear in pulmonary nodule during operation [J]. Tianjin Medical Journal, 2024, 52(9): 946-949.
[2]	QIN Hanlin, HU Changlu, ZHAO Yamei, NIU Weina. Effect and safety of quadruple regimen in preventing multi-day cisplatin-based chemotherapy induced nausea and vomiting [J]. Tianjin Medical Journal, 2024, 52(8): 835-839.
[3]	WANG Lei, MENG Kun, WANG Bing. Analysis of influencing factors of recurrent wheezing in children with bronchopneumonia and construction of prediction model [J]. Tianjin Medical Journal, 2024, 52(8): 850-853.
[4]	LI Dongsheng, QIN Yirong, QIAO Man, CHI Hang, CUI Qingmin, LI Xiaoqiu. Clinical effects of Qingke Pingchuan Granule on acute exacerbation of COPD [J]. Tianjin Medical Journal, 2024, 52(8): 854-857.
[5]	JIN Caifeng, WU Wei, WU Ke. Relationship between GBS infection, vaginal microecological changes and adverse pregnancy outcomes of pregnant women [J]. Tianjin Medical Journal, 2024, 52(8): 858-861.
[6]	HUANG Yuan, WANG Gang, LI Yanling, XIE Ping. Research progress on signaling pathways and drug intervention in radiation-induced heart disease [J]. Tianjin Medical Journal, 2024, 52(8): 888-892.
[7]	ZHANG Guohua, ZHANG Lingling, GAO Lan, LUO Junli, SHEN Yawen, LIU Lei, WANG Yuhua. Clinical analysis of 16 cases of connective tissue disease-associated interstitial lung disease complicated with lung cancer [J]. Tianjin Medical Journal, 2024, 52(7): 687-690.
[8]	WU Caixin, YAN Yan, DENG Yuanlin, DU Yamin, YANG Zhenwen, PAN Qing, YANG Fan. The value of cardiac magnetic resonance in evaluating severe pulmonary hypertension associated with connective tissue disease [J]. Tianjin Medical Journal, 2024, 52(7): 691-694.
[9]	SHI Yuru, SHI Ding. A comparative study of the treatment of GOV type gastric varices with large-volume band ligators and tissue glue combined with lauromacrogol injection [J]. Tianjin Medical Journal, 2024, 52(6): 604-609.
[10]	HUO Jingchen, WANG Yue, LI Hua, QIU Rong, SU Jingwei, WANG Zhuofan, YANG Jie. Predictive value of systemic immune inflammation index (SII) on long-term survival of patients with stage III squamous lung cancer treated with radical radiotherapy [J]. Tianjin Medical Journal, 2024, 52(6): 634-638.
[11]	SHAO Hongxia, WU Juanjuan, YU Hongzhi, WU Qi, WU Junping. Clinical features of hematogenous disseminated pulmonary tuberculosis complicated with intracranial tuberculosis [J]. Tianjin Medical Journal, 2024, 52(5): 495-498.
[12]	LIU Minglin, FENG Xia, CHEN Yixin, LENG Xingli, WANG Shaoqing. Correlation between plasma Aβ and P-tau181 levels and cognitive impairment in maintenance hemodialysis patients [J]. Tianjin Medical Journal, 2024, 52(5): 505-508.
[13]	SUN Junjie, GUO Sujie, LI Honglin, YUE Yingying, WANG Xingfen. Comparative study on the efficacy of photodynamic therapy and loop electrosurgical excision procedure in the treatment of grade 2 cervical intraepithelial neoplasia [J]. Tianjin Medical Journal, 2024, 52(5): 509-513.
[14]	WU Qian, WANG Yi, CHEN Nian, ZHOU Kai, TIAN Xin, XU Hui, GOU Xiaoxia. Effect of induction chemotherapy on immune function and inflammatory indicators in patients with nasopharyngeal carcinoma [J]. Tianjin Medical Journal, 2024, 52(4): 397-402.
[15]	FAN Hui, MA Yu, LI Ximing. Research progress in the prevention of contrast-related acute kidney injury [J]. Tianjin Medical Journal, 2024, 52(3): 327-330.